SAAD Centre for Diabetes and Pharmacy, School of Biomedical Sciences, University of Ulster, Cromore Road, Coleraine, Co. Londonderry, BT52 1SA, Northern Ireland, UK.
Expert Opin Investig Drugs. 2010 Sep;19(9):1039-48. doi: 10.1517/13543784.2010.513381.
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone that potentiates nutrient-induced insulin release. To date, the physiological importance of GIP has received much less attention than its younger sister incretin hormone glucagon-like peptide-1. Thus, it is worthwhile to refocus on this important and somewhat neglected incretin hormone.
The potential role of GIP as a treatment option for type 2 diabetes is highlighted. Furthermore, the use of GIP as a new therapeutic option for obesity, osteoporosis and cognitive impairment is also considered.
Long-acting GIP receptor agonists offer a potential new class of antidiabetic drugs. Furthermore, recent observations suggest an as yet untapped potential for GIP agonists in the treatment of osteoporosis and cognitive impairment. In addition, GIP is known to play a role in lipid metabolism and fat deposition. Accordingly, both genetic and chemical ablation of GIP signalling in mice with obesity-diabetes can protect against, or reverse, many of the obesity-associated metabolic disturbances. This review focuses on preclinical data generated to date.
GIP-based therapeutics have potential for the treatment of type 2 diabetes and obesity, with the possibility of further beneficial actions in osteoporosis and cognitive decline.
葡萄糖依赖性胰岛素释放多肽（GIP）是一种肠促胰岛素激素，可增强营养物质诱导的胰岛素释放。迄今为止，GIP 的生理重要性受到的关注远不及它的妹妹肠促胰岛素激素胰高血糖素样肽-1。因此，重新关注这种重要但有些被忽视的肠促胰岛素是值得的。
强调了 GIP 作为 2 型糖尿病治疗选择的潜在作用。此外，还考虑了将 GIP 用作肥胖症、骨质疏松症和认知障碍的新治疗选择。
长效 GIP 受体激动剂提供了一类有潜力的新型抗糖尿病药物。此外，最近的观察结果表明，GIP 激动剂在治疗骨质疏松症和认知障碍方面具有尚未开发的潜力。此外，已知 GIP 在脂质代谢和脂肪沉积中发挥作用。因此，肥胖型糖尿病小鼠中 GIP 信号的遗传和化学消融均可预防或逆转许多与肥胖相关的代谢紊乱。本篇综述重点介绍了迄今为止获得的临床前数据。
基于 GIP 的治疗方法具有治疗 2 型糖尿病和肥胖症的潜力，并且有可能在骨质疏松症和认知能力下降方面产生进一步的有益作用。
Zotero 插件